Mesenchymal Stem Cell Culture Medium for Homogeneous Cells and Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for isolating and cultivating mesenchymal stem cells from the amniotic membrane of the umbilical cord lack the ability to produce a highly homogenous population with enhanced wound healing properties, and there is a need for a method to improve these properties in mesenchymal stem cells for clinical applications.
Innovation Solution
A culture medium comprising DMEM, F12, M171, and FBS is used to cultivate mesenchymal stem cells, resulting in a population with at least 90% expression of CD73, CD90, and CD105 markers and minimal expression of CD34, CD45, and HLA-DR, enhancing the production of Angiopoietin 1 (Ang-1), TGF-β1, VEGF, and HGF, thereby improving wound healing properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional culture methods are used to isolate mesenchymal stem cells from amniotic membrane, then cell isolation is achieved, but the population homogeneity and wound healing properties are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the culture medium composition with specific ratios of DMEM, F12, and M171 media, along with controlled serum concentrations, to induce homogeneous mesenchymal stem cell populations with enhanced wound healing properties. This resolves the contradiction by achieving high homogeneity through precise parameter control rather than complex procedural steps
Solution Approach 2:
The invention uses a composite culture medium system combining three different basal media (DMEM, F12, M171) in specific proportions, creating a synergistic environment that promotes both cell homogeneity and wound healing capabilities. This composite approach achieves superior results without increasing procedural complexity
2Reliability
If existing isolation protocols are applied, then mesenchymal stem cells can be obtained, but wound healing properties are not enhanced
Solution Approach 1:
The patent enhances wound healing efficacy by modifying culture parameters including medium composition ratios and serum concentrations, which induce the expression of wound healing-related proteins in mesenchymal stem cells. This achieves improved reliability through parameter optimization rather than system complexity
Solution Approach 2:
The invention applies preliminary action by pre-conditioning mesenchymal stem cells in the optimized culture medium before clinical application, thereby enhancing their wound healing properties in advance. This prepares the cells with desired characteristics prior to use, improving reliability without requiring complex treatment protocols
3Productivity
If standard culture conditions are used, then cell cultivation is maintained, but production efficiency and safety for clinical trials are insufficient
Solution Approach 1:
The patent improves cell production efficiency by optimizing culture medium parameters and composition, which enhances cell proliferation and survival rates. This achieves higher productivity through parameter optimization rather than increasing procedural complexity
Solution Approach 2:
The optimized culture medium system serves multiple functions simultaneously: it supports cell proliferation, maintains population homogeneity, and enhances wound healing properties. This multi-functionality improves productivity without requiring separate complex protocols for each objective
Data Source
AI summary
The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.